{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:49:00Z","timestamp":1790513340175,"version":"4.1.0"},"reference-count":209,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T00:00:00Z","timestamp":1573344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic Myeloid Leukemia (CML) is a disease arising in stem cells expressing the BCR-ABL oncogenic tyrosine kinase that transforms one Hematopoietic stem\/progenitor Cell into a Leukemic Stem Cell (LSC) at the origin of differentiated and proliferating leukemic cells in the bone marrow (BM). CML-LSCs are recognized as being responsible for resistances and relapses that occur despite the advent of BCR-ABL-targeting therapies with Tyrosine Kinase Inhibitors (TKIs). LSCs share a lot of functional properties with Hematopoietic Stem Cells (HSCs) although some phenotypical and functional differences have been described during the last two decades. Subverted mechanisms affecting epigenetic processes, apoptosis, autophagy and more recently metabolism and immunology in the bone marrow microenvironment (BMM) have been reported. The aim of this review is to bring together the modifications and molecular mechanisms that are known to account for TKI resistance in primary CML-LSCs and to focus on the potential solutions that can circumvent these resistances, in particular those that have been, or will be tested in clinical trials.<\/jats:p>","DOI":"10.3390\/ijms20225616","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T04:07:07Z","timestamp":1573531627000},"page":"5616","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6654-9472","authenticated-orcid":false,"given":"Fabien","family":"Muselli","sequence":"first","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (Inserm) U1065, Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, CEDEX 3, 06204 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Peyron","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (Inserm) U1065, Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, CEDEX 3, 06204 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4136-3556","authenticated-orcid":false,"given":"Didier","family":"Mary","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (Inserm) U1065, Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, CEDEX 3, 06204 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1634\/theoncologist.9-3-259","article-title":"Optimizing treatment of chronic myeloid leukemia: A rational approach","volume":"9","author":"Stone","year":"2004","journal-title":"Oncologist"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.7314\/APJCP.2015.16.17.7415","article-title":"Chronic Myeloid Leukemia--Prognostic Value of Mutations","volume":"16","author":"Kaleem","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/cas.12849","article-title":"Novel oral transforming growth factor-beta signaling inhibitor EW-7197 eradicates CML-initiating cells","volume":"107","author":"Naka","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clml.2012.01.005","article-title":"Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia","volume":"12","author":"Cervera","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1172\/JCI127080","article-title":"SIRT1 regulates metabolism and leukemogenic potential in CML stem cells","volume":"130","author":"Abraham","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/leu.2012.65","article-title":"Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells","volume":"26","author":"Yu","year":"2012","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Deng, Y., Li, X., Feng, J., and Zhang, X. (2018). Overexpression of miR-202 resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2. Biosci. Rep., 38.","DOI":"10.1042\/BSR20171383"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood-2014-06-581926","article-title":"MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.18632\/oncotarget.23231","article-title":"Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K\/AKT\/mTOR pathway","volume":"9","author":"Tu","year":"2018","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1038\/onc.2017.85","article-title":"Interferon gamma is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells","volume":"36","author":"Madapura","year":"2017","journal-title":"Oncogene"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2011.285","article-title":"Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors","volume":"26","author":"Mak","year":"2012","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.exphem.2012.01.004","article-title":"ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34+ CD38(-) population to imatinib","volume":"40","author":"Airiau","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"30487","DOI":"10.18632\/oncotarget.5890","article-title":"Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells","volume":"6","author":"Carter","year":"2015","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Carter, B.Z., Mak, P.Y., Mu, H., Wang, X., Tao, W., Mak, D.H., Dettman, E.J., Cardone, M., Zernovak, O., and Seki, T. (2019). Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem\/progenitor cells in a murine model. Haematologica.","DOI":"10.3324\/haematol.2019.219261"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.18632\/oncotarget.1925","article-title":"The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors","volume":"5","author":"Ko","year":"2014","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/10428194.2010.546913","article-title":"Inhibition of autophagy: A new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors","volume":"52","author":"Calabretta","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1590\/S1516-84842009005000050","article-title":"Methylation status of the SOCS 1 and JUNB genes in chronic myeloid leukemia patients","volume":"31","author":"Pena","year":"2009","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1038\/leusup.2012.25","article-title":"Inhibition of autophagy with clarithromycin: A new strategy to enhance sensitivity of CML stem cells to tyrosine kinase inhibitors","volume":"1","author":"Carella","year":"2012","journal-title":"Leuk. Suppl."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3892\/ijo.2014.2313","article-title":"Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia","volume":"44","author":"Shao","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/1078-0432.CCR-12-1777","article-title":"Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia","volume":"19","author":"Katagiri","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41375-018-0252-4","article-title":"Targeting quiescent leukemic stem cells using second generation autophagy inhibitors","volume":"33","author":"Baquero","year":"2019","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2009.017178","article-title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis","volume":"95","author":"Vianello","year":"2010","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2016-05-714089","article-title":"Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI","volume":"129","author":"Agarwal","year":"2017","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/leu.2017.87","article-title":"Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo","volume":"31","author":"Zhou","year":"2017","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1158\/1078-0432.CCR-16-1298","article-title":"Gas6\/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing beta-Catenin","volume":"23","author":"Jin","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1080\/10428190903150847","article-title":"Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib","volume":"50","author":"Dillmann","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","article-title":"Kill one bird with two stones: Potential efficacy of BCR-ABL and autophagy inhibition in CML","volume":"118","author":"Helgason","year":"2011","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-13-0410","article-title":"Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo","volume":"13","author":"Beider","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-019-0427-7","article-title":"Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling","volume":"33","author":"Kuepper","year":"2019","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"24436","DOI":"10.18632\/oncotarget.8332","article-title":"BM microenvironmental protection of CML cells from imatinib through Stat5\/NF-kappaB signaling and reversal by Wogonin","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bbrc.2018.02.063","article-title":"Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress","volume":"497","author":"Wang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"298ra119","DOI":"10.1126\/scitranslmed.aab1740","article-title":"Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling","volume":"7","author":"Riether","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"25476","DOI":"10.1038\/srep25476","article-title":"Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia","volume":"6","author":"Irvine","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.18632\/oncotarget.2353","article-title":"Selective JAK2\/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem\/progenitor cells","volume":"5","author":"Lin","year":"2014","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbrc.2016.08.047","article-title":"Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk\/Mnk1\/eIF4E pathway","volume":"478","author":"Liu","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1172\/JCI66129","article-title":"Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival","volume":"124","author":"Chen","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Rauzan, M., Chuah, C.T., Ko, T.K., and Ong, S.T. (2017). The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174107"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1172\/JCI85239","article-title":"Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia","volume":"126","author":"Jin","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/jnci\/djx236","article-title":"Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition","volume":"110","author":"Mitchell","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4161\/15548627.2014.994368","article-title":"Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia","volume":"11","author":"Zeng","year":"2015","journal-title":"Autophagy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/0008-5472.CAN-09-3537","article-title":"Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62\/SQSTM1 expression and AMPK activation","volume":"70","author":"Puissant","year":"2010","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","article-title":"CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression","volume":"129","author":"Tarafdar","year":"2017","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/15548627.2016.1162359","article-title":"ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells","volume":"12","author":"Karvela","year":"2016","journal-title":"Autophagy"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ijc.28043","article-title":"Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem\/progenitor cells","volume":"133","author":"Babashah","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/leu.2011.67","article-title":"The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem\/progenitor cells","volume":"25","author":"Pellicano","year":"2011","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"E2298","DOI":"10.1073\/pnas.1301838110","article-title":"Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function","volume":"110","author":"Lim","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bbrc.2016.03.018","article-title":"Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem\/progenitor cell function","volume":"472","author":"Xiao","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood.V85.4.873.bloodjournal854873","article-title":"Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia","volume":"85","author":"Uckun","year":"1995","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Wicha","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature05372","article-title":"A human colon cancer cell capable of initiating tumour growth in immunodeficient mice","volume":"445","author":"Pollett","year":"2007","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exphem.2016.11.005","article-title":"Preclinical approaches in chronic myeloid leukemia: From cells to systems","volume":"47","author":"Clarke","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"24273","DOI":"10.1074\/jbc.M002094200","article-title":"The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells","volume":"275","author":"Sattler","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2004-03-0849","article-title":"Activation of the PI3K\/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species","volume":"105","author":"Kim","year":"2005","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-04-2416","article-title":"The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients","volume":"65","author":"Breedveld","year":"2005","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/bloodadvances.2016000810","article-title":"Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia","volume":"1","author":"Kinstrie","year":"2016","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: Stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semcancer.2017.07.006","article-title":"Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options","volume":"51","author":"Koschmieder","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrm2763","article-title":"Mechanisms of polycomb gene silencing: Knowns and unknowns","volume":"10","author":"Simon","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.stem.2014.05.006","article-title":"Chromatin repressive complexes in stem cells, development, and cancer","volume":"14","author":"Laugesen","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature01572","article-title":"Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells","volume":"423","author":"Lessard","year":"2003","journal-title":"Nature"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2010-02-270660","article-title":"BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells","volume":"116","author":"Rizo","year":"2010","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.bcmd.2014.07.002","article-title":"BMI1 gene expression in myeloid leukemias and its impact on prognosis","volume":"53","author":"Saudy","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/leu.2015.112","article-title":"The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells","volume":"29","author":"Mourgues","year":"2015","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","article-title":"The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia","volume":"110","author":"Mohty","year":"2007","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2010.65","article-title":"High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1038\/bcj.2013.54","article-title":"ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia","volume":"3","author":"Menezes","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2017-06-789669","article-title":"Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies","volume":"131","author":"Yang","year":"2018","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"key":"ref_99","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/onc.2012.83","article-title":"SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1182\/blood-2011-06-361691","article-title":"Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis","volume":"119","author":"Yuan","year":"2012","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.2003.08.166","article-title":"Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa","volume":"21","author":"Castillejo","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","article-title":"Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia","volume":"45","author":"Agirre","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3892\/ol.2010.208","article-title":"Increased BCR promoter DNA methylation status strongly correlates with favorable response to imatinib in chronic myeloid leukemia patients","volume":"2","author":"Koh","year":"2011","journal-title":"Oncol. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1365-2141.2003.04660.x","article-title":"Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia","volume":"123","author":"Liu","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1089\/gtmb.2012.0530","article-title":"The methylation status of the DDX43 promoter in Chinese patients with chronic myeloid leukemia","volume":"17","author":"Chen","year":"2013","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.clml.2014.06.072","article-title":"Epigenetic Silencing of P16 (INK4a) Gene by Promoter Hypermethylation in Chronic Myelogenous Leukemia","volume":"14","author":"Ahmad","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/S0959-8049(03)00552-5","article-title":"Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase","volume":"39","author":"Nagy","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7314\/APJCP.2014.15.1.75","article-title":"DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients","volume":"15","author":"Bodoor","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0609.2008.01178.x","article-title":"Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia","volume":"82","author":"Qian","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.leukres.2008.11.013","article-title":"sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia","volume":"33","author":"Pehlivan","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Jelinek, J., Gharibyan, V., Estecio, M.R., Kondo, K., He, R., Chung, W., Lu, Y., Zhang, N., Liang, S., and Kantarjian, H.M. (2011). Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022110"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/1878-0261.12191","article-title":"DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34(+) CD15(-) cells in early chronic-phase chronic myeloid leukemia","volume":"12","author":"Court","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2009.015693","article-title":"Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells","volume":"95","author":"Janssen","year":"2010","journal-title":"Haematologica"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","article-title":"Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nrg3594","article-title":"Gene regulation by antisense transcription","volume":"14","author":"Pelechano","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gene.2017.01.004","article-title":"Long noncoding RNA HULC promotes cell proliferation by regulating PI3K\/AKT signaling pathway in chronic myeloid leukemia","volume":"607","author":"Lu","year":"2017","journal-title":"Gene"},{"key":"ref_119","first-page":"1054","article-title":"CEBPA-mediated upregulation of the lncRNA PLIN2 promotes the development of chronic myelogenous leukemia via the GSK3 and Wnt\/beta-catenin signaling pathways","volume":"7","author":"Sun","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/onc.2014.131","article-title":"A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA","volume":"34","author":"Guo","year":"2015","journal-title":"Oncogene"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biopha.2018.05.047","article-title":"Long noncoding RNA MEG3 inhibits proliferation of chronic myeloid leukemia cells by sponging microRNA21","volume":"104","author":"Li","year":"2018","journal-title":"Biomed. Pharm."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","article-title":"Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth","volume":"6","author":"Agirre","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","article-title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia","volume":"95","author":"Flamant","year":"2010","journal-title":"Haematologica"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-4598-10-41","article-title":"Expression patterns of microRNAs associated with CML phases and their disease related targets","volume":"10","author":"Lopotova","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11010-013-1958-2","article-title":"Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia","volume":"390","author":"Zhu","year":"2014","journal-title":"Mol. Cell Biochem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ddr.21266","article-title":"miRNAs as Biomarkers in Chronic Myelogenous Leukemia","volume":"76","author":"Kotagama","year":"2015","journal-title":"Drug Dev. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-8-69","article-title":"MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations","volume":"8","author":"Garate","year":"2009","journal-title":"Mol. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"49451","DOI":"10.18632\/oncotarget.17706","article-title":"Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells","volume":"8","author":"Salati","year":"2017","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Li, Y., Yuan, Y., Tao, K., Wang, X., Xiao, Q., Huang, Z., Zhong, L., Cao, W., Wen, J., and Feng, W. (2013). Inhibition of BCR\/ABL protein expression by miR-203 sensitizes for imatinib mesylate. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061858"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nm.4499","article-title":"Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1634\/theoncologist.5-5-405","article-title":"Molecular abnormalities in chronic myeloid leukemia: Deregulation of cell growth and apoptosis","volume":"5","author":"Keeshan","year":"2000","journal-title":"Oncologist"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1023\/A:1009623222534","article-title":"Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells","volume":"5","year":"2000","journal-title":"Apoptosis"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Tzifi, F., Economopoulou, C., Gourgiotis, D., Ardavanis, A., Papageorgiou, S., and Scorilas, A. (2012). The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Adv. Hematol., 2012.","DOI":"10.1155\/2012\/524308"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.leukres.2015.08.014","article-title":"BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia","volume":"39","author":"Guillem","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood-2008-07-169110","article-title":"Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia","volume":"113","author":"Kim","year":"2009","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1128\/MCB.24.23.10289-10299.2004","article-title":"Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release","volume":"24","author":"Deming","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev-biochem-060815-014556","article-title":"Mammalian Autophagy: How Does It Work?","volume":"85","author":"Bento","year":"2016","journal-title":"Annu. Rev. Biochem."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Rothe, K., Porter, V., and Jiang, X. (2019). Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030461"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1182\/blood-2013-07-516807","article-title":"The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem\/progenitor cells","volume":"123","author":"Rothe","year":"2014","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood-2010-12-322537","article-title":"BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription","volume":"118","author":"Sheng","year":"2011","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2352-3026(15)00096-4","article-title":"Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: A phase 1 safety and pharmacokinetics study","volume":"2","author":"Martinelli","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1101\/gad.1617608","article-title":"Hypoxia regulates TSC1\/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling","volume":"22","author":"DeYoung","year":"2008","journal-title":"Genes Dev."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"96984","DOI":"10.18632\/oncotarget.18904","article-title":"Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence","volume":"8","author":"Ianniciello","year":"2017","journal-title":"Oncotarget"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","article-title":"Normal and leukemic stem cell niches: Insights and therapeutic opportunities","volume":"16","author":"Schepers","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-319-97746-1_6","article-title":"Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment","volume":"1100","author":"Shah","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI117333","article-title":"Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function","volume":"94","author":"Bhatia","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1182\/blood.V87.9.3883.bloodjournal8793883","article-title":"Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia","volume":"87","author":"Bhatia","year":"1996","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm1489","article-title":"Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells","volume":"12","author":"Krause","year":"2006","journal-title":"Nat. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2013-11-538694","article-title":"Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche","volume":"123","author":"Krause","year":"2014","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","article-title":"beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia","volume":"23","author":"Hu","year":"2009","journal-title":"Leukemia"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2013-05-501460","article-title":"Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression","volume":"122","author":"Laperrousaz","year":"2013","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1182\/blood-2017-08-801019","article-title":"Immature CML cells implement a BMP autocrine loop to escape TKI treatment","volume":"130","author":"Grockowiak","year":"2017","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.stem.2019.02.018","article-title":"Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells","volume":"24","author":"Agarwal","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","article-title":"Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib","volume":"26","author":"Weisberg","year":"2012","journal-title":"Leukemia"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2017.09.012","article-title":"Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph(+) chronic myeloid leukemia","volume":"57","author":"Willmann","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","article-title":"Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells","volume":"27","author":"Welner","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"12167","DOI":"10.1074\/jbc.RA119.008037","article-title":"Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7\/JAK1\/STAT5 pathway","volume":"294","author":"Zhang","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1038\/bcj.2015.109","article-title":"PPARgamma ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells","volume":"6","author":"Seferynska","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"248","DOI":"10.20892\/j.issn.2095-3941.2016.0023","article-title":"Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang","volume":"13","author":"Zhou","year":"2016","journal-title":"Cancer Biol. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","article-title":"HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","article-title":"Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition","volume":"123","author":"Ng","year":"2014","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e28781","DOI":"10.4161\/onci.28781","article-title":"IFNalpha induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia","volume":"3","author":"Ilander","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Bruck","year":"2018","journal-title":"Leukemia"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2141.2010.08453.x","article-title":"Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate","volume":"153","author":"Bachy","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Christiansson, L., Soderlund, S., Svensson, E., Mustjoki, S., Bengtsson, M., Simonsson, B., Olsson-Stromberg, U., and Loskog, A.S. (2013). Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055818"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/leu.2015.26","article-title":"Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells","volume":"29","author":"Riether","year":"2015","journal-title":"Leukemia"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","article-title":"A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease","volume":"74","author":"Sweet","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/10428199509059647","article-title":"Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha","volume":"18","author":"Pawelec","year":"1995","journal-title":"Leuk. Lymphoma"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1080\/1042819031000110973","article-title":"Immunological effects of interferon-alpha on chronic myelogenous leukemia","volume":"44","author":"Palma","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e1139","DOI":"10.1002\/cnr2.1139","article-title":"Metabolic underpinnings of leukemia pathology and treatment","volume":"2","author":"Nemkov","year":"2019","journal-title":"Cancer Rep."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"A, J., Qian, S., Wang, G., Yan, B., Zhang, S., Huang, Q., Ni, L., Zha, W., Liu, L., and Cao, B. (2010). Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013186"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1021\/acs.jproteome.6b00356","article-title":"Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients","volume":"15","author":"Karlikova","year":"2016","journal-title":"J. Proteome Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature22314","article-title":"Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia","volume":"545","author":"Hattori","year":"2017","journal-title":"Nature"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1158\/0008-5472.CAN-15-2887","article-title":"Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1\/Akt Axis in Breast Cancer","volume":"76","author":"Dou","year":"2016","journal-title":"Cancer Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Hu, J., Feng, M., Liu, Z.L., Liu, Y., Huang, Z.L., Li, H., and Feng, W.L. (2016). Potential role of Wnt\/beta-catenin signaling in blastic transformation of chronic myeloid leukemia: Cross talk between beta-catenin and BCR-ABL. Tumour Biol., 39.","DOI":"10.1007\/s13277-016-5413-3"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","article-title":"Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl","volume":"18","author":"Gregory","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI45977","article-title":"CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression","volume":"122","author":"Schurch","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/sj.onc.1201049","article-title":"Tyrosine phosphorylation of p120cbl in BCR\/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase","volume":"14","author":"Jain","year":"1997","journal-title":"Oncogene"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.4049\/jimmunol.159.10.4720","article-title":"Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients","volume":"159","author":"Chai","year":"1997","journal-title":"J. Immunol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/mcbr.2000.0231","article-title":"STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells","volume":"3","author":"Raaijmakers","year":"2000","journal-title":"Mol. Cell Biol. Res. Commun."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2008.27","article-title":"Targeting survival cascades induced by activation of Ras\/Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways for effective leukemia therapy","volume":"22","author":"McCubrey","year":"2008","journal-title":"Leukemia"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"503","DOI":"10.18388\/abp.2013_2014","article-title":"Role of anti-apoptotic pathways activated by BCR\/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors","volume":"60","author":"Danisz","year":"2013","journal-title":"Acta Biochim. Pol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/onc.2008.24","article-title":"FOXOs, cancer and regulation of apoptosis","volume":"27","author":"Fu","year":"2008","journal-title":"Oncogene"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia","volume":"25","author":"Samanta","year":"2011","journal-title":"Leukemia"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/leu.2010.257","article-title":"Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells","volume":"25","author":"Modi","year":"2011","journal-title":"Leukemia"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S2352-3026(18)30021-8","article-title":"Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: A single-centre, open-label, dose-escalation, phase 1\/1b trial","volume":"5","author":"Ohanian","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2011-06-361261","article-title":"Targeting of GSK3beta promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells","volume":"119","author":"Reddiconto","year":"2012","journal-title":"Blood"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.pharmthera.2006.02.006","article-title":"Mitotic kinases: The key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis","volume":"111","author":"Li","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/leu.2012.186","article-title":"MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1038\/bcj.2014.60","article-title":"A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"4","author":"Seymour","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: A population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: The paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/22\/5616\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:33:20Z","timestamp":1760189600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/22\/5616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,10]]},"references-count":209,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["ijms20225616"],"URL":"https:\/\/doi.org\/10.3390\/ijms20225616","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,10]]}}}